EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies

Juhui Han, So Yun Lim, Jaewon Hyung, Hyungwoo Cho, Dok Hyun Yoon, Sung-Han Kim

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Juhui Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematologic Neoplasms, Antibodies, Bispecific, Immunotherapy, Adoptive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea from the Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data exists on the incidence of CMV infections after chimeric antigen receptor (CAR) T‐cell or bispecific antibody (BsAb) therapy for hematologic malignancies.

Methods

We reviewed medical records of patients with hematologic malignancies treated with CAR T‐cells or BsAbs between July 2018 and October 2024 in a tertiary hospital in Seoul, South Korea. CMV infections were detected using CMV DNA qPCR assays performed within 180 days after CAR T‐cell infusion or the last BsAb treatment. Secondary outcomes were the occurrence of clinically significant CMV infections (CS‐CMVi) and end‐organ diseases.

Results

Of 179 patients, 76 (42%) received CAR T‐cell therapy, and 103 (58%) received BsAb therapy. The incidence of CMV infection was 62% in BsAb recipients, and 43% in CAR T‐cell recipients. Two (6.1% of total CMV infections) CAR T‐cell recipients had CS‐CMVi, and 1 (3.0%) developed possible CMV pneumonia. In the BsAb group, 10 (16% of total CMV infections) patients received antiviral therapy, and 4 (6.3%) had end‐organ diseases. Receiving three or more previous systemic chemotherapy regimens in the CAR T‐cell group was associated with increased CMV infection risks (HR 4.7, 95% CI 1.88–11.8, p < 0.001), and older age in the BsAb group had a trend toward having more CMV infection (HR 1.02, 95% CI 1.00–1.05, p = 0.06).

Conclusion

Approximately 43% and 62% of patients receiving CAR T‐cell and BsAb therapy had CMV infection, with 1%–4% developing CMV diseases. Effective strategies for preventing CMV infections in these patients are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematologic NeoplasmsAntibodies, BispecificImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedAgedAdultCytomegalovirusRetrospective StudiesIncidenceRepublic of Korea

Stichwörter der Autor:innen

bispecific antibodieschimeric antigen receptor T‐cell therapycytomegalovirus

Substanzen

Antibodies, BispecificReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Förderung

  • National Research Foundation of Korea from the Ministry of Science and ICT, South Korea

Zitieren

APA

Han, J., Lim, S. Y., Hyung, J., Cho, H., Yoon, D. H., & Kim, S. H. (2025). Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. Transplant Infectious Disease. https://doi.org/10.1111/tid.70138

Vancouver

Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH. Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. Transplant Infectious Disease. 2025. doi:10.1111/tid.70138

BibTeX
@article{Han2025,
  author = {Han, Juhui and Lim, So Yun and Hyung, Jaewon and Cho, Hyungwoo and Yoon, Dok Hyun and Kim, Sung-Han},
  title = {Cytomegalovirus Infection After Chimeric Antigen Receptor T‐Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70138}
}
Kostenlos starten →